Ligand Pharma Tops Q2 EPS by 60c
- ByInvesting.com-
Ligand Pharma (NASDAQ:LGND) reported Q2 EPS of $1.03, $0.60 better than the analyst estimate of $0.43. Revenue for the quarter came in at $57.4 million versus the consensus...
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ
Symbol | Exchange | Currency |
|---|
107.75
+1.39(+1.31%)
- Volume:33,686
- Day's Range:105.28 - 109.00
- 52 wk Range:72.57 - 169.98
LGND Overview
- Prev. Close
- 106.36
- Day's Range
- 105.28-109
- Revenue
- 240.42M
- Open
- 105.28
- 52 wk Range
- 72.57-169.98
- EPS
- -0.475
- Volume
- 33,686
- Market Cap
- 1.82B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 128,931
- P/E Ratio
- -
- Beta
- 1.12
- 1-Year Change
- -0.43%
- Shares Outstanding
- 16,882,751
- Next Earnings Date
- Nov 10, 2022
What is your sentiment on Ligand?
or
Vote to see community's results!
Ligand Pharmaceuticals Incorporated News
- Ligand Pharma Tops Q1 EPS by 10c
- ByInvesting.com-
Ligand Pharma (NASDAQ:LGND) reported Q1 EPS of $0.76, $0.10 better than the analyst estimate of $0.66. Revenue for the quarter came in at $45.7 million versus the consensus...
- Barclays Stick to Their Buy Rating for Ligand Pharma
- ByInvesting.com-
Barclays (LON:BARC) analyst Balaji Prasad maintained a Buy rating on Ligand Pharma (NASDAQ:LGND) on Thursday, setting a price target of $185, which is approximately 22.74% above...
Ligand Pharmaceuticals Incorporated Analysis
- Got A Stimulus Check? These 2 ETFs Are Worthy Investments
The U.S. government has started sending out the third round of direct stimulus checks to eligible Americans. For those readers who have decided to invest some or all of the...
- Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported fourth-quarter 2019 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 68 cents. The...
- Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported third-quarter 2019 adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate of 65 cents. The...
Ligand Pharmaceuticals Incorporated Company Profile
Ligand Pharmaceuticals Incorporated Company Profile
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Buy | Strong Buy | Strong Buy | Sell |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 265.12 | 265.59 | 261.26 | +2.94 | +1.12% | 939.53K | NYSE | |||
| 8.09 | 8.12 | 7.85 | -0.28 | -3.31% | 3.37M | NYSE | |||
| 100.63 | 101.85 | 99.80 | -0.20 | -0.20% | 36.63M | NASDAQ | |||
| 31.61 | 31.66 | 30.71 | -1.14 | -3.48% | 3.97M | NYSE | |||
| 175.57 | 179.33 | 171.85 | +4.39 | +2.56% | 3.22M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 1.16 | 1.19 | 1.15 | -0.0500 | -4.13% | 1.63M | NYSE | |||
| 166.01 | 166.41 | 165.13 | +0.71 | +0.43% | 3.86M | NYSE | |||
| 45.31 | 45.49 | 44.78 | -0.95 | -2.05% | 1.09M | NYSE | |||
| 3.525 | 3.55 | 3.47 | -0.075 | -2.08% | 7.08M | NYSE | |||
| 1.07 | 1.09 | 1.05 | -0.0300 | -2.73% | 74.86K | NYSE | |||
| 134.82 | 134.86 | 132.25 | +0.81 | +0.60% | 1.30M | NYSE | |||
| 49.72 | 50.06 | 49.40 | -0.40 | -0.79% | 6.04M | NYSE | |||
| 7.33 | 7.385 | 6.73 | +0.460 | +6.70% | 3.35M | NYSE | |||
| 39.26 | 40.38 | 38.81 | -1.48 | -3.64% | 2.90M | NYSE |
- Sep 02, 2021, 22:26$300 next week
- Jul 26, 2021, 10:29Earnings today.
- Feb 22, 2021, 19:19this could be another short squeeze
- Feb 19, 2021, 01:17Just bought
- Feb 05, 2021, 03:43let wall street bets know about this
- Feb 04, 2021, 21:54easy 300, high growth profitable company with lots of shorties to squeeze
- Feb 04, 2021, 14:46short squeeze, after the good earning result?
- Jan 24, 2021, 13:29short squeeze?
- Jun 17, 2019, 22:50Buy now
- May 03, 2019, 19:08What in the world